Cancerkin’s News Update…
Cancerkin and Hackney Chinese Community Services
As part of our ongoing awareness work in East London, the Cancerkin Team was at the Hackney Chinese Community Services centre last week to speak about being breast aware. They delivered their message in Cantonese to a group of 14 women, providing translated breast awareness leaflets in order to overcome any language barriers. The team will return this week to give another presentation to a Mandarin speaking group. We thank the centre for welcoming and supporting the team!
Last chance for early booking discount…
We are offering a special discounted rate to supporters booking before 31st July for Cancerkin’s performance of the Judas Kiss on Wednesday 10 October 2012. Tickets are usually £50 but we are offering a special rate of £45. So book now to secure your discount! Please visit our website to download a reservation form or contact Laura on email@example.com.
Working at Cancerkin…
We are currently recruiting for the exciting role of Events and Development Manager. If you or someone you know has an interest in events management and fundraising, and is interested in applying, please visit our website to find out more.
In the news…
Obesity and breast cancer treatment
Scientists at Breakthrough Breast Cancer have found that, after receiving treatment with hormone-suppressing drugs called aromatase inhibitors, women with breast cancer who are obese have higher levels of oestrogen that those of a normal weight. Over three quarters of breast cancers need the hormone oestrogen to grow and so one of the main ways to treat the disease is by blocking the production or activity of the hormone. Obese women have higher levels of the hormone than healthy-weight women and the study, published last week in the Journal of Medical Oncology, found that while the drugs markedly reduced levels of oestrogen in obese women, levels remained more than double those in women of a healthy weight. This suggests that obese and overweight women could benefit from changes to their treatment.
Researchers at the Institute of Cancer Research and the Royal Marsden examined two aromatase inhibitors. Another recent study has indicated that aromatase inhibitors are no more effective that tamoxifen in women with a higher BMI and so scientists wanted to investigate this possibility further. They examined 54 postmenopausal women who received three months of the drug anastrozole and three months of the more potent drug letrozole, or the drugs in the opposite order. Data on BMI and oestrogen levels was available for 44 women. Results showed that, prior to treatments, women with a BMI between 30 and 35 had three times more plasma oestrogen than those with a BMI under 25. After treatment with letrozole, women with a higher BMI still had levels of plasma oestrogen nearly three times as high as those with a normal BMI. Anastrozole produced the same trend but results were not of statistical significance.
Senior author Professor Mitch Dowsett said: “We found that women with higher BMIs had more oestrogen remaining in their blood after treatment than healthy-weight women, which is consistent with previous suggestions that aromatase inhibitors might be slightly less effective in these women. Our findings are based on laboratory studies, so we would need to carry out clinical trials to tell us whether women with a higher BMI would benefit from changes to their treatment. Women with higher BMIs should certainly not be alarmed by this finding or stop taking their treatment. Our study takes us a step closer to understanding which of the treatment options available might be the most suitable for individual women.”
To read more, please visit Breakthrough Breast Cancer’s website.